Navigation Links
Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
Date:4/20/2009

EMERYVILLE, Calif., April 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the poster presentation of significant, new data on the nature of the active compound and mechanism of action for its preclinical cancer drug candidate, BN108. The presentation is being made at the 2009 conference of the American Association of Cancer Research (AACR) in Denver, today.

In summary, the study concludes the following:

  • BN108, an aqueous extract of Anemarrhena asphodeloides, selectively induces cell death in breast cancer cells and other tumor cells without having a toxic effect on normal cells.
  • Timosaponin AIII (TAIII) has been identified as an active compound from BN108 that is responsible for the selective activity of BN108 towards breast cancer cells.
  • BN108 and TAIII rapidly and selectively inhibited major pro-survival cellular pathways that are often over-active in breast cancer.

"Currently available treatments for advanced breast cancer patients have limited efficacy and are associated with severe toxicity. Significantly more effective, less toxic therapies are urgently needed. Our studies suggest that therapeutic strategies based on BN108 and TspA3 may achieve more efficacious and safer clinical outcomes for breast cancer patients," stated Emma Shtivelman, Ph.D., the director of cancer research at Bionovo.

"BN108 offers great potential for the treatment of cancer. It is a drug that targets cell survival mechanisms, but it does it only in cancer cells. We anticipate it will have little to no collateral toxicity as is observed with all current cancer chemotherapy," said Isaac Cohen, chairman and CEO of Bionovo, Inc. "Bionovo is looking forward to entering clinical testing with BN108. We be
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo Announces 2008 Highlights and Year-End Financial Results
2. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
3. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
4. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
5. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
6. Bionovo to Present at the Piper Jaffray Healthcare Conference
7. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
8. Bionovo Reports Third Quarter 2008 Financial Results
9. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
10. Bionovo to Present at Canaccord Adams Global Growth Conference
11. Bionovo Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Novartis is ... study of CTL019, an investigational chimeric antigen receptor ... in the treatment of specific types of hard-to-treat ... by the University of Pennsylvania,s Perelman School of ... (r/r) diffuse large B-cell lymphoma (DLBCL) and follicular ...
(Date:6/1/2015)... IL (PRWEB) June 01, 2015 ... developing and manufacturing of chiral stationary phases (CSPs) ... options for its current and presenting solutions for ... to its portfolio. This valuable addition to its ... and effective advantage that can tackle projects for ...
(Date:6/1/2015)... 1, 2015  Boston-based Veritas Genetics is launching ... and bring personalized medicine and prevention to the ... their health. Beginning with its first product, a ... risk, Veritas Genetics is making its products affordable ... amount of genetic data which will be shared ...
(Date:6/1/2015)... MD (PRWEB) June 01, 2015 ... they have entered into a commercial collaboration agreement ... companies will combine their technologies and work together ... (MSC) regenerative technology. RoosterBio and Sistemic will collaborate ... technologies to build more precise and relevant characterization ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4
... Technologies LLC (Myriant), a privately-held, biotech developer and ... its Science Advisory Board and the appointment of ... will provide broad insight into all aspects of ... feedstocks into valuable chemicals. , (Logo: ...
... N.C., Oct. 21 Cornerstone Therapeutics Inc. (Nasdaq CM: ... and commercializing significant products primarily for the respiratory and ... conference call at 8:30 AM ET on Wednesday, November ... quarter ended September 30, 2009. Management will also ...
... ... business models capture investors, interest. , ... Miami, FL (PRWEB) October 21, 2009 -- iLife Americas, LLC, a ... in the U.S. to market its line of iLife wellness and therapeutic products. Officially ...
Cached Biology Technology:Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 3iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets 2
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... and the Veterans Affairs Greater Los Angeles Healthcare System ... the cost-effectiveness of current modern drugs for treating hepatitis ... Published in the May 17 Annals of Internal Medicine, ... decisions. Researchers note that a degree of uncertainly exists ...
... known for a long time that only 2% -- 3% ... of our genomes -- often referred to as junk DNA ... RNA, reverse-transcribed into DNA, and then reinserted into a new ... class of these retroelements. Retroviruses can insinuate themselves into the ...
... Don't miss out the cool movies, link at the end ... Medicine researchers have found a way to exercise a little ... their wings, and fly on command by triggering genetic "remote ... central nervous systems, according to a new report in the ...
Cached Biology News:UCLA study assesses cost-effectiveness of Hepatitis B drugs 2UCLA study assesses cost-effectiveness of Hepatitis B drugs 3Chimp genome reveals a retroviral invasion 2Chimp genome reveals a retroviral invasion 3Remote control flies? Fly behavior controlled by laser light 2Remote control flies? Fly behavior controlled by laser light 3
...
5 minutes from gel band to purified DNA...
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
...
Biology Products: